文献速递肿瘤 PET/CT

18F-阿法肽II用于乳腺癌患者腋窝淋巴结评估:与18F-FDG的比较

18F-Alfatide II for the evaluation of axillary lymph nodes in breast cancer patients: comparison with 18F-FDG.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-02-09

44例临床疑诊乳腺癌女性患者在一周内先后接受18F-阿法肽II与18F-FDG PET/CT,37例经病理确诊乳腺癌(腋窝淋巴结转移17例、非转移20例)。18F-阿法肽II目视分析的灵敏度70.6%、特异度90%、准确率81.1%;两者联合后灵敏度显著提高至82.4%、阴性预测值显著提高至85.0%。

要点

  • 18F-阿法肽II检测转移性腋窝淋巴结高特异度(90%)但灵敏度相对较低(70.6%)。
  • 18F-阿法肽II与18F-FDG联合后灵敏度显著提高至82.4%、NPV显著提高至85.0%。
  • 18F-阿法肽II的T/NT在各项半定量参数中约登指数最高(76.5%)、特异度100%。

核心结论

  • 18F-阿法肽II可用于乳腺癌患者转移性腋窝淋巴结的检测,但与18F-FDG一样具有高特异度而灵敏度相对较低。
  • 18F-阿法肽II与18F-FDG联合可显著提高灵敏度与阴性预测值。
  • 18F-阿法肽II的T/NT可能是评估腋窝淋巴结最重要的半定量参数。

研究设计与样本

  • 共纳入44例临床疑诊乳腺癌的女性患者,均在一周内接受18F-阿法肽II与18F-FDG PET/CT检查。
  • 44例中37例经病理确诊为乳腺癌,其中腋窝淋巴结转移17例、非转移20例。
  • 腋窝淋巴结的示踪剂摄取采用目视分析及SUVmax、SUVmean、靶/非靶比值(T/NT)半定量分析评估。

主要发现

  • 目视分析灵敏度、特异度、准确率、阳性预测值、阴性预测值:18F-阿法肽II为70.6%、90%、81.1%、85.7%、78.3%,18F-FDG为64.7%、90%、78.4%、84.6%、75%。
  • 两者联合后灵敏度显著提高至82.4%,特异度为85%,准确率提高至83.8%,阳性预测值为82.4%,阴性预测值显著提高至85.0%。
  • 3例管腔B型(luminal B)亚型对18F-阿法肽II与18F-FDG均为假阴性;18F-阿法肽II另2例假阴性为三阴性亚型,18F-FDG另3例假阴性亦为管腔B型亚型。
  • 18F-阿法肽II的SUVmax、SUVmean、T/NT曲线下面积(AUC)在0.8至0.9之间,而18F-FDG相应参数AUC均大于0.9。
  • 18F-阿法肽II的T/NT约登指数最高(76.5%),特异度100%、准确率89.2%、阳性预测值100%。

关键数值与推荐

  • 18F-阿法肽II目视分析灵敏度70.6%、特异度90%、准确率81.1%、阳性预测值85.7%、阴性预测值78.3%。
  • 18F-FDG目视分析灵敏度64.7%、特异度90%、准确率78.4%、阳性预测值84.6%、阴性预测值75%。
  • 联合18F-阿法肽II与18F-FDG后灵敏度82.4%、特异度85%、准确率83.8%、阳性预测值82.4%、阴性预测值85.0%。
  • 18F-阿法肽II的T/NT约登指数76.5%、特异度100%、准确率89.2%、阳性预测值100%。

临床怎么用

  • 18F-阿法肽II可用于乳腺癌患者转移性腋窝淋巴结的检测,但灵敏度相对较低。
  • 18F-阿法肽II与18F-FDG联合可显著提高灵敏度和阴性预测值。
  • 18F-阿法肽II的T/NT可能作为评估腋窝淋巴结最重要的半定量参数。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: 18F-Alfatide II has been translated into clinical use and been proven to have good performance in identifying breast cancer. In this study, we investigated 18F-Alfatide II for evaluation of axillary lymph nodes (ALN) in breast cancer patients and compared the performance with 18F-FDG. METHODS: A total of 44 female patients with clinically suspected breast cancer were enrolled and underwent 18F-Alfatide II and 18F-FDG PET/CT within a week. Tracer uptakes in ALN were evaluated by visual analysis, semi-quantitative analysis with maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), and SUVmax ratio of target/non-target (T/NT). RESULTS: Among 44 patients, 37 patients were pathologically diagnosed with breast cancer with metastatic (17 cases) or non-metastatic (20 cases) ALN. The sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) of visual analysis were 70.6%, 90%, 81.1%, 85.7%, and 78.3% for 18F-Alfatide II, 64.7%, 90%, 78.4%, 84.6%, and 75% for 18F-FDG, respectively. By combining 18F-Alfatide II and 18F-FDG, the sensitivity significantly increased to 82.4%, the specificity was 85%, the accuracy increased to 83.8%, the PPV was 82.4%, and the NPV significantly increased to 85.0%. Three cases of luminal B subtype were false negative for both 18F-Alfatide II and 18F-FDG. The other 2 false negative cases of 18F-Alfatide II were triple-negative subtype and 3 false negative cases of 18F-FDG were luminal B subtype too. The AUCs of three semi-quantitative parameters (SUVmax, SUVmean, T/NT) for 18F-Alfatide II were between 0.8 and 0.9, whereas those for 18F-FDG were more than 0.9. 18F-Alfatide II T/NT had the highest Youden index (76.5%), specificity (100%), accuracy (89.2%), and PPV (100%) among these semi-quantitative parameters. 18F-Alfatide II uptake as well as 18F-FDG uptake in metastatic axillary lymph nodes (MALN) was significantly higher than that in benign axillary lymph nodes (BALN). Both 18F-Alfatide II and 18F-FDG did not show difference in primary tumor uptake irrespective of ALN status. CONCLUSION: 18F-Alfatide II can be used in breast cancer patients to detect metastatic ALN, however, like 18F-FDG, with high specificity but relatively low sensitivity. The combination of 18F-Alfatide II and 18F-FDG can significantly improve sensitivity and NPV. 18F-Alfatide II T/NT may serve as the most important semi-quantitative parameter to evaluate ALN.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wu J, Tian J, Zhang Y, et al. 18F-Alfatide II for the evaluation of axillary lymph nodes in breast cancer patients: comparison with 18F-FDG. Eur J Nucl Med Mol Imaging. 2022. PMID: 35138445. doi:10.1007/s00259-021-05333-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。